Asia’s cell and gene therapy industry is investing in long-term global opportunities, especially in CAR-T, CAR-NK, Stem cell and iPSC-based cell therapies, CRISPR-based gene therapies, genome-editing technologies and many more.  Likewise, global investors and partners are keen on developing relationships with Asia’s cell and gene therapy...